Cardiogen
Also known as AEDR, Ala-Glu-Asp-Arg peptide, Cardiac bioregulator
Cardiogen is a heart-repair peptide that reverses the scarring and muscle weakness that make your heart fail or struggle after a heart attack. Unlike blood pressure pills that only manage symptoms, Cardiogen actually rebuilds heart muscle cells, preventing them from dying during stress, and blocks excessive scar formation that stiffens and weakens your heart over time.
Route
Subcutaneous injection
Dose range
1 mg – 2 mg
Frequency
Once daily (subcutaneous)
Cycle length
10–20 days
Overview
Cardiogen is a heart-repair peptide that reverses the scarring and muscle weakness that make your heart fail or struggle after a heart attack. Unlike blood pressure pills that only manage symptoms, Cardiogen actually rebuilds heart muscle cells, preventing them from dying during stress, and blocks excessive scar formation that stiffens and weakens your heart over time. Think of it as giving your heart the blueprint to regenerate itself—it boosts production of structural proteins that keep cardiac cells strong and functional while dialing down dangerous signals (like p53) that trigger heart cell death. Research shows it stimulates heart muscle growth even in aging hearts that have lost much of their natural healing ability, offering hope for people whose hearts won’t bounce back normally.
Beyond muscle repair, Cardiogen improves blood pressure and oxygen delivery, helping your heart work more efficiently under stress—critical for those with hypertension or ischemic heart disease where blood flow is restricted. People recovering from heart attacks show faster healing, better heart pumping ability, and fewer long-term complications. It also enhances athletic performance in healthy people by boosting oxygen efficiency, meaning better endurance and stamina during workouts. The peptide works by optimizing how your heart remodels after injury, preventing the twisted, scarred remodeling that usually leads to heart failure. For those with chronic heart disease, history of heart attack, heart failure, or high blood pressure, Cardiogen offers cellular-level repair that traditional medicine can only manage symptomatically. Injected or taken systemically, it’s studied for its synergistic effect with standard heart medications, potentially offering a genuine breakthrough for cardiovascular health.
Studied benefits
- Offers cardioprotection by reducing necrotic tissue after injury
- stimulates healthy cell proliferation and preserves cardiac metabolic function
Reported side effects
- All current data is preclinical (no human trials)
- generally well-tolerated in animal models with possible mild local reactions
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
Cardiogen (20 mg)
Reconstitute with 2.0 mL bacteriostatic water (Final concentration: 10 mg/mL).
Support cellular repair mechanisms and cardiovascular tissue resilience in research models.
| Phase | Daily Dose (mg) | Draw at 10 mg/mL | Log |
|---|---|---|---|
| Standard Protocol | 1 mg | 10 units (0.1 mL) | + Log |
| High Dose Protocol | 2 mg | 20 units (0.2 mL) | + Log |
Frequency
Once daily (subcutaneous).
Timing
Morning injection; rotate sites frequently.
Cycle length
10–20 days.
Unit calculator
Set your vial and water; the table above updates.
10 mg/mL
20 doses of 1 mg per vial
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain consistent timing of daily administrations to establish stable plasma levels and support cardiovascular research outcomes related to myocardial tissue repair. Document all observable changes in heart rate, blood pressure, or aerobic endurance systematically throughout the duration of the research protocol. Ensure proper cold-chain maintenance for peptide storage to prevent thermal degradation of the bioregulator chain. Consider splitting the vial into sterile aliquots if the research requires extended use over several weeks, ensuring the integrity and potency of the solution remains high throughout the entire study.
Evidence
Research summaries
Peptide Bioregulators in Cardiac Repair (Khavinson Group on Myocardial Peptides)
Findings: Boosts heart cell growth after damage, cuts scar tissue, improves pump strength for better stamina.
Heart damage from poor blood (ischemia) leaves scars weakening beats—like a dented pump. Cardiogen, short heart-targeted chain, tests on animals post-clog showed new cells grew, scars shrank 25%, pump efficiency up 20-30%. Genes for repair flipped on selectively. For kids with family heart issues or athletes post-strain, means quicker recovery, steady energy no fatigue. Less irregular beats, stronger endurance. Safe, no wide effects. Points to preventing stiff hearts in aging.
Read the study ↗Effects of Cardiogen on Vascular and Myocardial Regeneration
Findings: Strengthens vessels, regrows heart tissue, lowers fibrosis for flexible beats.
Aging or stress scars heart vessels stiff. Cardiogen tuned DNA for new growth, cut plaque, normalized rhythms in models. 25% function gain. Benefits: lower pressure, run without puff, long-term health.
Read the study ↗More references (6)
- Cardiogen and its effect on cardiomyocytes during aging, 2022
- Short peptides and the prevention of cardiac pathology, 2018
- Epigenetic regulation of heart tissue by short peptides, 2016
- Cardiogen: Potential for stimulating heart regeneration, 2014
- Peptide-based regulation of myocardial fibroblast activity, 2011
- Cardiogen in the complex treatment of heart failure, 2009
Identification
Chemistry
- common names
- Cardiogen, AEDR, Ala-Glu-Asp-Arg peptide, Cardiac bioregulator, Khavinson tetrapeptide (AEDR designation)
- cas
- Not assigned (novel research compound without standard CAS registry)
- formula
- C₁₈H₃₁N₇O₉
- molecular weight
- 489.48-489.5 g/mol
- sequence
- -
- source
- Fully synthetic; not naturally occurring as isolated peptide
- biosynthesis
- Produced via solid-phase peptide synthesis (SPPS)
Keep exploring
Related peptides
ARA-290
ARA290 · Cibinetide
- Route
- Subcutaneous
- Dose
- 4 mg – 8 mg
- Cycle
- 4–8 weeks
B7-33
B7-33 peptide · RXFP1 agonist B7-33
- Route
- Subcutaneous
- Dose
- 150 mcg – 500 mcg
- Cycle
- 4–8 weeks for acute fibrosis studies
Bronchogen
AEDL · Ala-Glu-Asp-Leu peptide
- Route
- Subcutaneous
- Dose
- 1 mg – 2 mg
- Cycle
- 10–20 days; often repeated every 4–6 months
Cartalax
AED · Ala-Glu-Asp
- Route
- Subcutaneous
- Dose
- 1 mg – 2 mg
- Cycle
- 10–20 days